Premium
SB431542 treatment promotes the hypertrophy of skeletal muscle fibers but decreases specific force
Author(s) -
Watt Kevin I.,
Jaspers Richard T.,
Atherton Phillip,
Smith Ken,
Rennie Michael J.,
Ratkevicius Aivaras,
Wackerhage Henning
Publication year - 2010
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.21573
Subject(s) - myostatin , myogenesis , myogenin , myosin , muscle hypertrophy , skeletal muscle , smad2 protein , chemistry , xenopus , myocyte , phosphorylation , smad , microbiology and biotechnology , medicine , endocrinology , biology , biochemistry , gene
Abstract The small molecule inhibitor SB431542 inhibits activin type I receptors. The muscle growth‐inhibitor myostatin binds to and signals via these receptors. The aim of this study was to test the hypothesis that SB431542 can inhibit myostatin‐related Smad signaling and induce muscle growth in cultured C2C12 myotubes and increase growth and specific force in cultured Xenopus muscle fibers. The effect of SB431542 was assessed in vitro on C2C12 myotubes and ex vivo using mature Xenopus muscle fibers. SB431542 treatment reduced myostatin‐induced C‐terminal Smad2 phosphorylation and resulted in the formation of enlarged myotubes. However myogenin expression was unchanged, while p70 S6k phosphorylation at Thr389, total myosin heavy chain, and the rate of protein synthesis were all reduced. Mature Xenopus muscle fibers that were treated with SB431542 had a higher fiber cross‐sectional area but decreased specific force production than control. SB431542 can initially antagonize myostatin signaling, but long‐term unexpected signaling effects occur. Muscle fibers hypertrophy, but their specific force decreases compared to control. Muscle Nerve, 2010